To determine the frequency of Wnt/Wingless b catenin pathway alteration in human hepatocellular carcinoma, a b catenin and APC gene mutation screening was performed in a series of 119 tumors. An activating b catenin mutation in exon 3 was found in 18% of the cases. Among tumors lacking b catenin mutation, no APC mutation has been evidenced in a subset of 30 cases tested. The correlation between b catenin mutation status and chromosome segment deletions was studied on a set of 48 hyperploid tumors. Chromosome 1p, 4q and 16p deletions were signi®cantly associated with the absence of b catenin mutation (P50.05). Furthermore the Fractional Allelic Loss was signi®cantly smaller in the b catenin mutated tumors than in the non-mutated tumors (0.12 versus 022). Taken together, these results suggest, the existence of two carcinogenesis mechanisms. The ®rst mechanism implies a b catenin activating mutation associated with a low rate of loss of heterozygosity. The second mechanism, operating in a context of chromosomal instability, would involve tumor suppressor genes.
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Keywords: hepatocellular carcinoma; beta-catenin; CNNTB1; allelic losses; APC; mutation; chromosome 4 Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide. Risk factors such as hepatitis B (HBV) and C (HCV) virus infection, dietary exposure to a¯atoxine B1, alcohol consumption and several genetic diseases predisposing to cirrhosis are strongly associated with the occurrence of HCC. However, cellular transformation mechanisms elicited by these etiologic agents remain unclear. The few genetic alterations that were reported in HCC include p53, IGF2R, K-ras, N-ras and RB1 mutations and, on rare occasions, insertional mutagenesis of cellular genes by HBV integration (Bressac et al., 1990; de Souza et al., 1995; Tada et al., 1990; de TheÂ et al., 1987; Wang et al., 1990; Graef et al., 1994) . Cytogenetic studies (Simon et al., 1990; Bardi et al., 1992) , and more recently comparative genomic hybridization and high density allelotypes showed recurrent allelic losses on chromosome 1p, 4q, 6q, 8p, 9p, 13q, 16p, 16q and 17p (Marchio et al., 1997; Boige et al., 1997; Nagai et al., 1997) . Apart from chromosomes 17p, 13q and 6q for which losses can be related to p53, RB1 or IGF2R inactivation, the implication of several other tumor suppressor genes in HCC remains to be elucidated.
Recently, in c-Myc and H-Ras transgenic mice developing HCC, an activation of the Wnt/Wingless b catenin pathway was reported (de la Coste et al., 1998) . Beta catenin activating mutations at the GSK3 phosphorylation site were found in 50% of the cases in these models. In human colon cancer this pathway was frequently shown to be activated through b catenin accumulation due to APC inactivation (54%) or b catenin stabilizing mutation in exon 3 (24%; Sparks et al., 1998) . In human HCC, a b catenin mutation resulting in a protein stabilization was observed in 18 ± 26% of the cases (de la Coste et al., 1998; . Furthermore, intracellular accumulation of wild type b catenin was found to be elevated in HCC in c-Myc and H-Ras transgenic mice, suggesting alteration of another pathway's member (de la Coste et al., 1998) .
To re®ne the frequency of Wnt/Wingless b catenin pathway alterations in human HCC, b catenin and APC gene mutation were screened for mutations in a series of 119 tumors. In all cases, primary HCC and matched non-tumor liver tissues were collected in French surgery departments from 1994 to 1998. The ®rst 48 hyperploid tumors were studied for loss of heterozygosity (LOH) through a genome-wide scan (Boige et al., 1997) . b catenin exon 3 was selected for mutation screening because it encodes the NH2-terminal regulatory domain of the protein previously found to bear activating mutations (Morin et al., 1997; Rubinfeld et al., 1997) . In 119 HCC cases a PCR fragment with the expected size was obtained between b catenin exon 2 and 4, demonstrating the absence of genomic deletions as was described for colorectal cancer and liver cancer de la Coste et al., 1998) . Sequencing of the resulting PCR fragments revealed a mutation of b catenin exon 3, in 21 cases, with intron/exon boundaries remaining normal. In 17 cases, a unique base-pair change inducing a missense mutation was found. In 14 cases, these point-mutations alter one of the ®ve serine or threonine targets of phosphorylation by GSK3 which is essential for the down-regulation of b catenin. In the remaining three cases unique substitution alters an amino acid adjacent to serine 33 (D32Y, D32G and G34R, Table 1 ). Previously, aspartic acid 32 and glycine 34 were found to be mutated in ten human HCC cases, one human colorectal cancer and ®ve azoxymethane-induced rat colon tumors (de la Coste et al., 1998; Sparks et al., 1998; Takahashi et al., 1998; Miyoshi et al., 1998) . Codon 32 or 34 alterations may likely aect phosphorylation of the serine 33 and appeared more frequently in HCC than in other tumor types. In case CHC035 an in-frame 27 base pair deletion was found, including serine 33. No repeats were found at the deletion boundaries. Finally, in each of the cases CHC072, CHC131 and CHC074, multiple alterations of b catenin were observed. No information was obtained on the involvement of a single or both alleles in the same tumor. However, in each case of multiple-alterations, at least one amino-acid altered in unique-mutation cases is implicated. Even though the functional mechanism underlying b catenin multiplemutations is not clear, double-mutations in dierent alleles were already described in two cases of azoxymethane-induced rat colon tumors (Takahashi et al., 1998) .
Relationship between the b catenin status (i.e. mutated or not mutated) and the available clinicohistological parameters were determined (Table 2) . No correlation was found between the presence of a b catenin mutation and the established risk factors of HCC. Furthermore, no relationship was found between histological parameters and presence of a b catenin mutation in our series of HCC. CHC028  CHC138  CHC130  CHC051  CHC046  CHC085  CHC107  CHC013  CHC150  CHC011  CHC134  CHC037  CHC104  CHC040  CHC097  CHC054  CHC030  CHC131   CHC072   CHC074  CHC035   GAC  GAC  TCT  TCT  GGA  TCT  ACC  ACC  ACC  ACC  TCT  TCT  TCT  TCT  TCT  TCT  TCT  TCT  TCT  AGT  GAC  TCT  ATC  TCT GGT  TGG...TCT   GGC  TAC  TTT  CTT  AGA  TAT  GCC  GCC  GCC  ATC  TTT  TTT  TTT  TTT  CCT  CCT  CCT  CCT  GCT  CGT  GCC  TCC  AGC  TGG  del 27 bases   D32G  D32Y  S33F  S33L  G34R  S37Y  T41A  T41A  T41A  T41I  S45F  S45F  S45F  S45F  S45P  S45P  S45P  S45P  S37A  S23R  D32A  S33S  I35S  delS37+G38W  delW257S33 DNA extraction was performed on frozen tissue fragments using the Qiaquick extraction kit (Qiagen). For b-catenin, a 630 base pair genomic PCR fragment spanning codon 1 (exon 2) to codon 92 (exon 4) was ampli®ed using primers primers BCATEX2F (GAAAATC-CAGCGTGGACAATG) and BCATEX4R (TCGAGTCATTGCA-TACTGTCC) PCR ampli®cations were performed on a 9600 Perkin Elmer DNA cycler, in a volume of 40 ml using the following procedure: initial denaturation step, 968C for 60 s, 35 cycles with a denaturation step at 948C for 20 s, annealing at 608C for 30 s, extension at 728C for 120 s, following by a ®nal extension at 728C for 7 min. For each DNA ampli®cation, AmpliTaq (0.5 unit, Perkin Elmer) was used together with 20 ng of genomic DNA, 12 pmoles of each speci®c primer, 0.8 mM of dNTPs and 1.5 mM of MgCl2. Sequencing reactions were performed on puri®ed PCR fragments (QIAquick PCR puri®cation kit, Quiagen) using primer ABS30 (TTGATGGAGTTGGACATGG) and ABS32 (AGTGAAGGACT-GAGAAATCC), located in exon 3, and a PRISM big dye terminator kit (Applied Biosystems). All sequences were analysed on both strands on an ABI 377 sequencer with the AutoAssembler software (Applied Biosystems). The somatic nature of mutations was con®rmed by sequencing DNA derived from non-tumoral corresponding tissue. Mutated bases are underlined Clinical and histological evaluations were available for 98 cases. The mean age of the patient was 58 years (range, 27 ± 76 years) and the sex ratio was 5 : 1 (male : female), Hepatitis B surface antigen (HBsAg) was detected in the serum of 26 patients. Hepatitis C virus (HCV) infection was detected in 30 patients with enzyme-linked immunosorbent assay (Orthodiagnostic Systems) and was con®rmed by a recombinant immunoblot assay (Chiron Diagnostics). No evidence for HBsAg and antibodies against HCV was found in 39 patients. In 12 cases, HCC had developed in the absence of known liver disease. Pathological features recorded for each tumor were size, vascular invasion, grade of dierentiation according to the Edmondson and Steinert classi®cation and presence of cirrhosis. ns: non signi®cative In all cases DNA content of nucleu prepared from tumors was analysed using a FACStar PLUS¯ow cytometer (Becton Dickinson, San Jose, CA, USA) as described in Boige et al. (1997) . Allelic losses were determined according to the procedure described in Boige et al. (1997) . ns: non signi®cative Beta-catenin mutations in hepatocellular carcinoma P Legoix et al Among the 98 tumors that did not carry b catenin mutations, 30 tumors were randomly selected for APC mutations screening. It was performed between codons 682 and 1692, a region accounting for more than 70% of all APC mutations in colon cancer . The Protein Truncation Test revealed a normal protein fragment in all screened HCC, suggesting that APC mutation is not frequent in HCC. This result is consistent with the absence of recurrent LOH on chromosome 5q in HCC (Boige et al., 1997; Nagai et al., 1997) . However, other genes participating to the Wnt/Wingless cascade remain to be tested.
In the ®rst 48 hyperploid HCC of this series, LOH was previously analysed by a high-resolution allelotype (Boige et al., 1997) . Chromosome segments that were the most frequently aected by deletion were 8p (60%), 17p (48%), 1p (44%), 4q (42%), 16p (40%), 16q (39%), 6q (35%), 9p (30%) and 13q (29%). Among these, chromosome 1p, 4q and 16p deletions were signi®cantly associated with the absence of b catenin mutations (Table 3 ). Considering the fact that losses of chromosome 1p, 4q and 16q are strongly associated in this hyperploid series of HCC (Boige et al., 1997) , we have con®rmed the correlation between these three chromosome segments and the absence of b catenin mutations, by genotyping the whole set of 119 HCC with chromosome 4q markers (P50.02, Table 3 ). Furthermore, Fractional Allelic Loss (FAL) in the ®rst 48 hyperploid tumors, was signi®cantly lower in the b catenin mutated tumors group than in the group of tumors lacking b catenin mutation (Table 3) . Taken together, these results suggest, as in colorectal cancer, the existence of two carcinogenesis mechanisms. The ®rst mechanism implicates a b catenin activating mutation, associated with a low rate of LOH. The second mechanism, operative in a context of chromosomal instability, would involve tumor suppressor genes belonging (or not) to the Wnt/Wingless pathway. As demonstrated by the frequent deletion of chromosome 1p, 4q, and 16q in HCC (Bardi et al., 1992; Marchio et al., 1997; Nagai et al., 1997; Boige et al., 1997) inactivation of tumor suppressor genes appear to be the most common carcinogenesis mechanism in HCC. Tumor suppressor genes on chromosomes 1p, 4q and 16q that are aected in hepatic carcinogenesis remain to be identi®ed. Candidate genes should be tested, particularly the Axin gene, a partner of the Wingless cascade, located on chromosome 16p (Zeng et al., 1997) . The inactivation of this gene could be an alternative way for b catenin accumulation in tumor cells.
